CSF Biomarker‐Based Cognitive Trajectories in Parkinson's Disease‐Subjective Cognitive Decline

Documenti analoghi

• Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease
  di: Saul Martinez‐Horta, et al.
  Pubblicazione: (2024)
• Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4‐Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers
  di: Arnau Puig‐Davi, et al.
  Pubblicazione: (2024)
• Early BMI Change, Cognitive Decline, and CSF AD Biomarkers Alterations in Parkinson's Disease
  di: Rui Zhong, et al.
  Pubblicazione: (2025)
• Plasma p‐tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study
  di: Giulia Giacomucci, et al.
  Pubblicazione: (2025)
• CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals
  di: Juan P. Vazquez, et al.
  Pubblicazione: (2025)